---
document_datetime: 2025-09-08 16:40:48
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/yaxwer-epar-all-authorised-presentations_en.pdf
document_name: yaxwer-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9487809
conversion_datetime: 2025-12-24 22:24:31.013549
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| EMA Number       | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/25/1934/001 | Yaxwer            | 120 mg     | Solution for injection | Subcutaneous use          | vial (glass)          | 1.7 ml (70 mg/ml)         | 1 vial      |
| EU/1/25/1934/002 | Yaxwer            | 120 mg     | Solution for injection | Subcutaneous use          | vial (glass)          | 1.7 ml (70 mg/ml)         | 3 vials     |
| EU/1/25/1934/003 | Yaxwer            | 120 mg     | Solution for injection | Subcutaneous use          | vial (glass)          | 1.7 ml (70 mg/ml)         | 4 vials     |